Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
XOMA Royalty Corporation (NASDAQ:XOMA)

Organization & Developments: XOMA

Parents

* XOMA’s business model is inherently diversified across several therapeutic areas and is exposed to the upside potential of biopharma innovation without as many clinical trial risks and potentially offers more stable returns.
*Biotechnology royalty aggregator that obtains milestone and royalty rights from investigational and commercial drugs
*More than 45 companies have licensed Xoma technology for making proteins in bacteria
*XOMA’s business model is to provide non-dilutive funding to biotech companies, allowing them to fund their research without dilution.
2006: XOMA was awarded a $31 million contract from NIAID for antibody development work against botulinum neurotoxin
2007: No operating profit as of 2007
2021: Since the company’s pivot to royalty aggregation in 2017, it has accumulated over 70 programs, yet none have reached commercial stage.
2021: Xoma Gets The Spotlight
2022: XOMA (XOMA) Investor Presentation - Slideshow_seekingalpha.com
2024: Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
2024: XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
2025: XOMA Royalty Corporation: High-Risk Royalty Aggregator Best Avoided
Lucentis
RAPTIVA® (efalizumab)
Schering-Plough Research Institute formed a collaboration with Xoma for the development of therapeutic antibodies for up-front p